Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy

Luis A. Carvajal; Ulrich Steidl

doi:10.1016/j.stem.2016.06.005

Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy

Luis A. Carvajal, Ulrich Steidl

Cell Biology

Research output: Contribution to journal › Short survey › peer-review

2 Scopus citations

Abstract

Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.

Original language	English (US)
Pages (from-to)	6-8
Number of pages	3
Journal	Cell Stem Cell
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/j.stem.2016.06.005
State	Published - Jul 1 2016

ASJC Scopus subject areas

Molecular Medicine
Genetics
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.stem.2016.06.005

Cite this

@article{7578e406a791435788c85222f3e56241,

title = "Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy",

abstract = "Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.",

author = "Carvajal, {Luis A.} and Ulrich Steidl",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = jul,

day = "1",

doi = "10.1016/j.stem.2016.06.005",

language = "English (US)",

volume = "19",

pages = "6--8",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy

AU - Carvajal, Luis A.

AU - Steidl, Ulrich

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.

AB - Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.

UR - http://www.scopus.com/inward/record.url?scp=85008601750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008601750&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2016.06.005

DO - 10.1016/j.stem.2016.06.005

M3 - Short survey

C2 - 27392220

AN - SCOPUS:85008601750

SN - 1934-5909

VL - 19

SP - 6

EP - 8

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 1

ER -

Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this